Discovery of Benzopyridone-Based Transient Receptor Potential Vanilloid 1 Agonists and Antagonists and the Structural Elucidation of Their Activity Shift.
Shivaji A ThoratYoonji LeeAeran JungJihyae AnnSongyeon AhnJisoo BaekDongxu ZuoNayeon DoJin Ju JeongPeter M BlumbergTimothy E EschNoe A TurciosLarry V PearceHee-Jin HaYoung Dong YooSunhye HongSun ChoiJeewoo LeePublished in: Journal of medicinal chemistry (2021)
Among a series of benzopyridone-based scaffolds investigated as human transient receptor potential vanilloid 1 (TRPV1) ligands, two isomeric benzopyridone scaffolds demonstrated a consistent and distinctive functional profile in which 2-oxo-1,2-dihydroquinolin-5-yl analogues (e.g., 2) displayed high affinity and potent antagonism, whereas 1-oxo-1,2-dihydroisoquinolin-5-yl analogues (e.g., 3) showed full agonism with high potency. Our computational models provide insight into the agonist-antagonist boundary of the analogues suggesting that the Arg557 residue in the S4-S5 linker might be important for sensing the agonist binding and transmitting signals. These results provide structural insights into the TRPV1 and the protein-ligand interactions at a molecular level.
Keyphrases
- molecular docking
- binding protein
- structure activity relationship
- endothelial cells
- neuropathic pain
- tissue engineering
- cerebral ischemia
- small molecule
- human health
- amino acid
- protein protein
- risk assessment
- high throughput
- atomic force microscopy
- brain injury
- anti inflammatory
- blood brain barrier
- subarachnoid hemorrhage